Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II

Cellular Immunology

Volumn 246, Issue 2, 2007, Pages 92-102

  Yao, Yongxue ^a   Li, Ping ^a   Singh, Pratibha ^a   Thiele, Allison T ^a   Wilkes, David S ^a   Renukaradhya, Gourapura J ^a   Brutkiewicz, Randy R ^a   Travers, Jeffrey B ^a   Luker, Gary D ^b   Hong, Soon Cheol ^a   Blum, Janice S ^a   Chang, Cheong Hee ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Dendritic cell; Gene regulation; Innate immunity; MHC class II; Type I interferon; Vaccinia virus

Indexed keywords

BETA INTERFERON; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CELL SURFACE; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINIA; VACCINIA VIRUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON TYPE I; MICE; MICE, INBRED C57BL; PHENOTYPE; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

MUS; VACCINIA VIRUS;

EID: 34548127274     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2007.06.005     Document Type: Article

References (55)

1. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93 (1996) 11341-11348
2. Wollenberg A., and Engler R. Smallpox, vaccination and adverse reactions to smallpox vaccine. Curr. Opin. Allergy Clin. Immunol. 4 (2004) 271-275
3. Rosenthal S.R., Merchlinsky M., Kleppinger C., and Goldenthal K.L. Developing new smallpox vaccines. Emerg. Infect Dis. 7 (2001) 920-926
4. Smith G.L., Symons J.A., Khanna A., Vanderplasschen A., and Alcami A. Vaccinia virus immune evasion. Immunol. Rev. 159 (1997) 137-154
5. McFadden G. Smallpox: an ancient disease enters the modern era of virogenomics. Proc. Natl. Acad. Sci. USA 101 (2004) 14994-14995
6. Yewdell J.W., and Hill A.B. Viral interference with antigen presentation. Nat. Immunol. 3 (2002) 1019-1025
7. Brutkiewicz R.R., Klaus S.J., and Welsh R.M. Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression. Nat. Immun. 11 (1992) 203-214
8. Boshkov L.K., Macen J.L., and McFadden G. Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. J. Immunol. 148 (1992) 881-887
9. Bennink J.R., and Yewdell J.W. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Top. Microbiol. Immunol. 163 (1990) 153-184
10. Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., Boyle D., Chan S., and Smith G. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168 (1988) 1211-1224
11. Xu R., Johnson A.J., Liggitt D., and Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172 (2004) 6265-6271
12. Battegay M., Bachmann M.F., Burhkart C., Viville S., Benoist C., Mathis D., Hengartner H., and Zinkernagel R.M. Antiviral immune responses of mice lacking MHC class II or its associated invariant chain. Cell Immunol. 167 (1996) 115-121
13. Li P., Wang N., Zhou D., Yee C.S., Chang C.H., Brutkiewicz R.R., and Blum J.S. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J. Immunol. 175 (2005) 6481-6488
14. Lanzavecchia A., and Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 106 (2001) 263-266
15. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20 (2002) 621-667
16. Austyn J.M. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 183 (1996) 1287-1292
17. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3 (2002) 265-271
18. Inaba K., Turley S., Iyoda T., Yamaide F., Shimoyama S., Reis e Sousa C., Germain R.N., Mellman I., and Steinman R.M. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. 191 (2000) 927-936
19. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2 (2002) 151-161
20. Nakano H., Yanagita M., and Gunn M.D. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194 (2001) 1171-1178
21. + dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172 (2004) 1996-2000
22. Haeryfar S.M. The importance of being a pDC in antiviral immunity: the IFN mission versus Ag presentation?. Trends Immunol. 26 (2005) 311-317
23. Beignon A.S., Skoberne M., and Bhardwaj N. Type I interferons promote cross-priming: more functions for old cytokines. Nat. Immunol. 4 (2003) 939-941
24. Zuniga E.I., McGavern D.B., Pruneda-Paz J.L., Teng C., and Oldstone M.B. Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nat. Immunol. 5 (2004) 1227-1234
25. Dalod M., Hamilton T., Salomon R., Salazar-Mather T.P., Henry S.C., Hamilton J.D., and Biron C.A. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J. Exp. Med. 197 (2003) 885-898
26. + T cells and subsequently express CD8alpha and CD205 molecules. J. Exp. Med. 195 (2002) 1233-1245
27. Alcami A., and Smith G.L. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71 (1992) 153-167
28. Smith G.L. Vaccinia virus glycoproteins and immune evasion. The sixteenth Fleming Lecture. J. Gen. Virol. 74 Pt 9 (1993) 1725-1740
29. Harte M.T., Haga I.R., Maloney G., Gray P., Reading P.C., Bartlett N.W., Smith G.L., Bowie A., and O'Neill L.A. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197 (2003) 343-351
30. Drillien R., Spehner D., Bohbot A., and Hanau D. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 268 (2000) 471-481
31. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., and Bhardwaj N. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163 (1999) 6762-6768
32. Luker K.E., Hutchens M., Schultz T., Pekosz A., and Luker G.D. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341 (2005) 284-300
33. Yao Y., Li W., Kaplan M.H., and Chang C.H. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J. Exp. Med. 201 (2005) 1899-1903
34. Yuwen H., Cox J.H., Yewdell J.W., Bennink J.R., and Moss B. Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology 195 (1993) 732-744
35. Gourley T., Roys S., Lukacs N.W., Kunkel S.L., Flavell R.A., and Chang C.H. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production. Immunity 10 (1999) 377-386
36. Chang C.H., Fontes J.D., Peterlin M., and Flavell R.A. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 180 (1994) 1367-1374
37. Yao Y., Xu Q., Kwon M.J., Matta R., Liu Y., Hong S.C., and Chang C.H. ERK and p38 MAPK signaling pathways negatively regulate CIITA gene expression in dendritic cells and macrophages. J. Immunol. 177 (2006) 70-76
38. Toshchakov V., Jones B.W., Perera P.Y., Thomas K., Cody M.J., Zhang S., Williams B.R., Major J., Hamilton T.A., Fenton M.J., and Vogel S.N. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 3 (2002) 392-408
39. Jenne L., Hauser C., Arrighi J.F., Saurat J.H., and Hugin A.W. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther. 7 (2000) 1575-1583
40. Werfel T., Witter W., and Gotze O. CD11b and CD11c antigens are rapidly increased on human natural killer cells upon activation. J. Immunol. 147 (1991) 2423-2427
41. Lima M., Almeida J., dos Anjos Teixeira M., Queiros M.L., Justica B., and Orfao A. The "ex vivo" patterns of CD2/CD7, CD57/CD11c, CD38/CD11b, CD45RA/CD45RO, and CD11a/HLA-DR expression identify acute/early and chronic/late NK-cell activation states. Blood Cells Mol. Dis. 28 (2002) 181-190
42. Turley S.J., Inaba K., Garrett W.S., Ebersold M., Unternaehrer J., Steinman R.M., and Mellman I. Transport of peptide-MHC class II complexes in developing dendritic cells. Science 288 (2000) 522-527
43. Ling P.D., Warren M.K., and Vogel S.N. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J. Immunol. 135 (1985) 1857-1863
44. Ransohoff R.M., Devajyothi C., Estes M.L., Babcock G., Rudick R.A., Frohman E.M., and Barna B.P. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J. Neuroimmunol. 33 (1991) 103-112
45. Kato T., Kitaura M., Inaba K., Watanabe Y., Kawade Y., and Muramatsu S. Suppression of macrophage Ia antigen expression by endogenous interferon-alpha/beta. J. Interferon Res. Spec. No. (1992) 29-41
46. Lu H.T., Riley J.L., Babcock G.T., Huston M., Stark G.R., Boss J.M., and Ransohoff R.M. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J. Exp. Med. 182 (1995) 1517-1525
47. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., and Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434 (2005) 772-777
48. Diebold S.S., Montoya M., Unger H., Alexopoulou L., Roy P., Haswell L.E., Al-Shamkhani A., Flavell R., Borrow P., and Reis e Sousa C. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424 (2003) 324-328
49. van den Broek M.F., Muller U., Huang S., Aguet M., and Zinkernagel R.M. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69 (1995) 4792-4796
50. Cebulla C.M., Miller D.M., Zhang Y., Rahill B.M., Zimmerman P., Robinson J.M., and Sedmak D.D. Human cytomegalovirus disrupts constitutive MHC class II expression. J. Immunol. 169 (2002) 167-176
51. Behboudi S., Moore A., Gilbert S.C., Nicoll C.L., and Hill A.V. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. Vaccine 22 (2004) 4326-4331
52. Drillien R., Spehner D., and Hanau D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 85 (2004) 2167-2175
53. Honda K., Sakaguchi S., Nakajima C., Watanabe A., Yanai H., Matsumoto M., Ohteki T., Kaisho T., Takaoka A., Akira S., Seya T., and Taniguchi T. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc. Natl. Acad. Sci. USA 100 (2003) 10872-10877
54. Le Bon A., and Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14 (2002) 432-436
55. Mathew A., Ennis F.A., and Rothman A.L. Transient decreases in human T cell proliferative responses following vaccinia immunization. Clin. Immunol. 96 (2000) 100-107